The prognosis of patients with refractory/relapsed acute myelogenous leukemia (rAML) is poor. Recent studies have shown that more transplant centers are choosing allogeneic peripheral blood stem cell transplantation (allo-PBSCT) for recipients, even with a higher leukemia burden. The purpose of the present study is to evaluate the outcome of rAML patients undergoing allo-PBSCT and to determine whether the disease status can predict the post-transplantation survival. The outcome of 58 patients (median age, 34 years; range, 14 to 52) with rAML who underwent allo-PBSCT in our institution from January 2000 until September 2011 was retrospectively studied. Thirty-three patients had complete remission (CR) before PBSCT, whereas 25 patients had no remission. Donors were matched related (31 patients) and unrelated (27 patients). Reducedintensity conditioning was used for 18 patients with rAML, and myeloablative conditioning was used for others. Sixty-six consecutive non-rAML patients (median age, 33 years; range, 15 to 51) who received an allo-PBSCT at the same period were used as a control. Full donor-type engraftment was achieved in all patients. After a median follow-up of 61 months, the 5-year overall survival of rAML patients was 54.21% AE 7.06%, which was lower than non-rAML patients (71.82% AE 6.4%, P ¼ .0386). However, the 5-year event-free survival for rAML and non-rAML patients had no statistical significance (53.54% AE 6.87% versus 62.07% AE 6.78%, P ¼ .2626). The 5-year overall survival between rAML patients who had CR and no remission before PBSCT was 56.06% AE 9.2% and 51.85% AE 10.83%, respectively (P ¼ .6408). These data demonstrate that allo-PBSCT is a promising and safe choice for the treatment of rAML, and the results were partially due to the rapid tapering of immunosuppressants in the early stage after PBSCT and prophylactic donor lymphocyte infusion. Meanwhile, the patients who did not achieve CR before PBSCT could also benefit from allo-PBSCT.
INTRODUCTION
Despite intensive remission induction chemotherapy, the clinical outcomes of relapsed/refractory acute myelogenous leukemia (rAML) are dismal. Further improvements in survival are unlikely to be achieved with traditional approaches such as standard or even high-dose chemotherapy [1] [2] [3] . Otherwise, a high incidence of relapses in those who already obtained remission after chemotherapy is a major hindrance to the long-term survival of patients with AML; even higher relapse rates appeared in rAML patients because of the larger tumor burden. Therefore, the treatment of patients with rAML remains challenging [4] [5] [6] .
Allogeneic hematologic stem cell transplantation (HSCT) is a curative treatment for refractory or relapsed acute leukemia, and it has been shown to decrease the risk of disease relapse when compared with chemotherapy and is now established as the treatment of choice in eligible patients with rAML [7] [8] [9] [10] . Advanced transplantation strategies have increased the survival by 10% per decade [11] . The improved transplantation protocol for high-risk patients with AML has shown promising results in first complete remission (CR) [12] and can cure approximately one third of patients with primary refractory AML [13] . With convenient collection and faster neutrophil and platelet engraftment, more transplant centers are choosing allogeneic peripheral blood stem cell transplantation (allo-PBSCT) for recipients, and several advancements have reduced the toxicity associated with HSCT [14] [15] [16] [17] [18] . Unfortunately, long-term survival of allo-PBSCT is limited by the morbidity and mortality related to relapse of the primary disease and complications of HSCT. The long-term benefits of the PBSCT and whether all rAML patients should benefit from it remain controversial [19, 20] . The growing number of survivors creates a need to optimize the PBSCT procedure and identify whether the disease status and some other factors related to patients' characteristics and transplantation procedures can affect the outcome of transplantation. Thus, we retrospectively examined the potential factors affecting the outcome of 58 patients with rAML in comparison with 66 consecutive non-rAML patients who underwent allo-PBSCT at our center between January 2000 and September 2011.
METHODS

Patient Characteristics
Patients were included in the rAML group if they fulfilled the following criteria: primary failure to achieve a CR after two cycles of standard induction therapy, relapse after a first CR of fewer than 6 months, second or higher relapse, and relapsed disease not responding to intensive salvage therapy [21] [22] [23] . In our center, AML patients with a suitable donor who satisfied the above criteria proceeded directly to PBSCT without further salvage chemotherapy if they also preferred HSCT. From January 2000 to September 2011, 58 consecutive patients with rAML underwent allo-PBSCT in our institute. Complete remission was defined as <5% blasts in the bone marrow and normalization of the peripheral blood count without circulating blasts. Patients were not eligible for allo-PBSCT if they had severe concomitant medical or psychiatric illnesses. Data on patients were censored in December 2011.
All patients signed informed consent forms before starting the conditioning therapy. The median bone marrow blasts were 19% (range, 0% to 47%) in the rAML group before PBSCT. The median age was 34 years old (range,14 to 52). Thirty-three of 58 rAML patients (57%) achieved CR before PBSCT, whereas 25 patients (43%) had no remission (NR). Thirty-one patients had a matched-related donor and 27 patients had unrelated donors. Twenty unrelated donors came from the Chinese Marrow Donor Program, and 7 unrelated donors came from the Buddhist Tzu Chi Stem Cells Center.
Twenty five patients (43%) in the rAML group had chromosomal abnormalities. Seven patients had poor chromosomal abnormality defined as follows: À5/del5q, À7, 3q, or 11p abnormalities; translocations t(4;11), t(1;19), t (3;3), t(6;9), inv (3) (q21;q26.2); and complex karyotypes (three or more chromosome abnormalities) [24] .
For the purpose of comparing with the rAML group, we screened all standard-risk AML patients who received an allo-PBSCT during the same period with remission status before transplantation as the control group (non-rAML group) in our institute with the following eligibility criteria: CR after one or two cycles of primary induction chemotherapy, relapse only once after CR of longer than 6 months, and attaining CR again after one or two salvage therapies. These patients usually received one to three strengthening chemotherapies while searching for the donor or preparing for PBSCT. A total of 66 consecutive AML patients were included in the study as the control. The median age of non-rAML group was 33 years (range, 15 to 51). Three patients in the non-rAML group had poor chromosomal abnormalities.
The rAML and non-rAML groups were comparable in terms of age, gender, human leukocyte antigen (HLA) matching, donor type, conditioning regimen, and graft-versus-host disease (GVHD) prophylaxis (P > .05). Detailed information about patients and transplant characteristics are listed in Table 1 .
HLA Typing
For all patients, genomic high-resolution typing by polymerase chain reaction (PCR)-based sequence-specific primer or PCR-based sequencespecific oligonucleotide probe techniques were used for HLA typing. HLA-A, -B and -DRB1 were typed for patients with related donors and HLA-C and -DQB1 were added in patients with unrelated donors. All patients with related donor (n ¼ 31, 53%) were HLA fully matched (6/6), whereas for patients with unrelated donors (n ¼ 27, 47%), 15 patients had a one-allele mismatched donor (9/10 alleles), 3 patients a two-allele mismatched donor (8/10 alleles), and the others a fully matched (10/10 alleles) donor.
Stem Cell Mobilization and Cell Counts
For PBSC mobilization, all donors were treated with granulocyte colony-stimulating factor (5 mg/kg, administered subcutaneously once daily) for 5 days before apheresis. In all rAML patients, the median number of mononuclear cells infused was 5. 
Engraftment
Absolute neutrophil count (ANC) and platelets (PLT) were used to evaluate graft function. We recorded the time of the first 3 consecutive days when ANC was .5 Â 10 9 /L and PLT was 20 Â 10 9 /L after PBSCT. Platelet engraftment satisfied the following conditions: (1) no platelet transfusion was given on or between the first and third days of counts and (2) the three counts were at least 24 hours apart. The gender chromosome and/or realtime PCR of short tandem repeat were used for chimerism monitoring.
Graft-Versus-Host Disease
Acute GVHD (aGVHD) was graded in five degrees [25] : 0 or absent and grades I, II, III, and IV. Only patients alive on day !100 were eligible for chronic GVHD (cGVHD) evaluation and outcome analysis, which was divided into limited and extensive groups [26] .
Conditioning Regimen and GVHD Prophylaxis
Reduced-intensity conditioning (RIC) transplantation was developed to reduce the toxicity of conditioning regimens, decrease the incidence of GVHD, and preserve a curative antitumor effect corresponding to allo-HSCT [27] [28] [29] . To further optimize the outcome of RIC transplantation for acute leukemia, in 2007, 5 years ago our transplantation center designed an RIC regimen we named FBA consisting of fludarabine, cytosine arabinoside, and busulfan. To ensure its usefulness in rAML patients, 18 patients (31%) with rAML were prepared with RIC-FBA (fludarabine, 30 mg/m 2 /day on days À10 to À6; busulfan, .8 mg/kg every 6 hours on days À5 to À3; cytosine arabinoside, 1.5 g/m 2 /day on days À10 to À6 i.v.), whereas other rAML patients received myeloablative conditioning regimen, including 30 patients (52%) conditioned with cyclophosphamide (60 mg/kg/day for 2 days) and total body irradiation (total 7 to 8 Gy; 6 to 7 Gy for lungs) with or without VP16 (10 mg/kg/d for 2 days i.v.) and 10 patients (17%) administered busulfan (.8 mg/kg every 6 hours for 4 days i.v.) and cyclophosphamide (60 mg/kg/day for 2 days i.v.). Antithymocyte globulin (Fresenius , Germany, 5 mg/kg/day for 4 days i.v.) was supplied to patients undergoing unrelated donor PBSCT. GVHD prophylaxis consisted of cyclosporine A (CsA), methotrexate, and mycophenolate mofetil. Methotrexate was administered at doses of 15 mg on day 1 and 10 mg on days 3 and 6 after PBSCT. Mycophenolate mofetil was administered at doses of 1 g twice a day from day 1 until day 30 after transplantation. Intravenous CsA (2 to 3 mg/kg daily) was administered from day À2 to day þ30 until no gastrointestinal reaction occurred; the patient was then switched to oral drug administration (4 to 5 mg/kg daily). We measured the plasma CsA levels once a week after PBSCT and kept the level between 200 and 400 ng/mL. After transplantation, the patients who had no aGVHD at the early stage would have CsA rapidly tapered. For these patients, CsA was tapered from day þ45 to þ90 and discontinued by day þ120. From day þ60 prophylactic donor lymphocyte infusion (DLI) was recommended in patients without aGVHD. At our center, frozen storage donor-derived stem cells grafts were used as the source of DLI. It was given in a doseescalating way to achieve a sustained graft-versus-leukemia (GVL) effect with limited risk of GVHD. DLI was repeated at 4-to 6-week intervals up to three times with the initial cell dose of 1 to 2 Â . On the date of last follow-up in patients without the respective event, the data were censored. Actuarial probabilities of OS, EFS, TRM, and RR were calculated using the Kaplan-Meier method, and the log-rank test (univariate) was used to evaluate differences between curves.
Statistical analyses comparing demographic and disease-specific variables used the t test for continuous variables and the chi-square test for categorical variables. SPSS 11.5 was used to perform the statistical analyses (Statistics Institute, Second Military Medical University, Shanghai, China). All P values were two sided, with P ＜ .05 indicating statistical significance by single analysis. The 95% confidence interval (CI) was calculated for standard error computation.
RESULTS
Engraftment
All 58 rAML patients and 66 non-rAML patients achieved engraftment. The day to median ANC > .5 Â 10 9 /L and the day to median PLT > 20 Â 10 9 /L were 13 days (range, 10 to 28 days) and 14 days (range, 9 to 60 days) in rAML, respectively. The difference of engraftment time between the rAML and non-rAML group was not statistically significant (P ¼ .276 [ANC]; P ¼ .937 [PLT] ). At day þ30, all patients had donor chimerism, and no primary graft failure was observed.
Acute and Chronic GVHD aGVHD was scored in four patients (7%) as grade Ⅰ, eight patients (14%) as grade Ⅱ, and five patients (8%) as gradea Ⅲ to Ⅳ in rAML at a median of 28 days (range, 7 to 82). Compared with the rAML group, grades Ⅰ, Ⅱ, and Ⅲ to Ⅳ aGVHD appeared in, respectively, 3, 19, and 4 patients (5%, 29%, and 6%) of non-rAML group at a median of 30 days (range, 8 to 84) (P ¼ .723). Except for one patient who died of severe aGVHD with infection, 57 rAML patients survived longer than 100 days after PBSCT and were eligible for evaluation of cGVHD. Forty-six patients (81%) developed cGVHD at a median of 157 days (range, 101 to 904) in the rAML group, including 39 patients (68%) with limited cGVHD and 7 patients (13%) with extensive cGVHD. The incidence of cGVHD in the rAML group was higher than that in the nonrAML group (P ¼ .041). Detailed information about GVHD is listed in Table 1 .
Forty-one rAML patients (71%) who had no aGVHD underwent a rapidly tapered CsA. Among them, 22 patients (54%) had prophylactic DLI, including 10 patients with DLI only one time, 8 patients twice, and 4 patients three times. After DLI, aGVHD grades Ⅱ to Ⅲ was triggered in nine patients (41%), whereas cGVHD was triggered in six patients (27%). The median time of aGVHD and cGVHD occurring after DLI was 25 days (range, 17 to 53) and 113 days (range, 101 to 186), respectively.
OS and EFS
The median follow-up in rAML and non-rAML was 61 months (range, 3 to 132) and 63 months (range, 3 to 130), respectively. At time of last follow-up, 34 patients (59%) were alive in the rAML group. Twenty-four patients in the rAML group died due to relapse (n ¼ 12) and transplant-related disease (n ¼ 12). Most deaths (95%) occurred within the first 3 years after transplantation. The probability of 5-year OS in rAML patients were 54.21% AE 7.06%. Fifty-one patients (77%) in the non-rAML group were alive, and 8 patients died from transplant-related disease and 7 patients from relapse. Compared with rAML, the probability of 5-year OS in nonrAML was 71.82% AE 6.4% (P ¼ .0386). (Figure 1A ). However, there was no statistical significance in EFS between the two groups. The probability of 5-year EFS in rAML and non-rAML groups were 53.54% AE 6.87% and 62.07% AE 6.78%, respectively (P ¼ .2626). (Figure 1B ). Multivariate analysis showed no significant predictors of OS and EFF (Table 2 ).
Relapse and TRM
Fifteen patients (26%) of all rAML experienced leukemia relapse at a median of 6 months (range, 2 to 36) after transplantation. Three patients who experienced relapse achieved CR and sustained it after DLI with or without chemotherapy. The other 12 patients died of relapse and failed to respond to therapy. In all non-rAML patients, 13 patients (20%) experienced leukemia relapse at a median of 8 months (range, 2.3 to 37.7) after transplantation. Seven patients died, and the other 6 patients achieved and sustained CR after DLI with or without chemotherapy. The probability of 5-year RR was 30.9% AE 6.85% in the rAML group and 26.6% AE 6.62% in the non-rAML group (P ¼ .4194) (Figure 2A) .
Twelve patients in the rAML group died of TRM, including serious infection (n ¼ 5), interstitial pneumonia (n ¼ 3), severe aGVHD (n ¼ 1), and extensive cGVHD with infection (n ¼ 3). Eight patients in the non-rAML group died of TRM. The causes of death were serious infection (n ¼ 4), interstitial pneumonia (n ¼ 3), and extensive cGVHD (n ¼ 1). The probability of 5-year TRM was 25.11% AE 6.32% in the rAML group and 14.22% AE 4.76% in the non-rAML group (P ¼ .2076) ( Figure 2B ). Multivariate analysis showed significant predictors of RR. Only the noneRIC-FBA conditioning regimen was significantly associated with a higher risk of TRM (relative risk, .5; 95% CI, .1 to .8; P ¼ .036), however ( Table 2) .
Survival Analyses in rAML Patients with CR versus NR before PBSCT
Thirty-three patients (57%) in the rAML group received allo-PBSCT during CR and the rest of patients (43%) without CR (NR). Twenty patients (61%) were alive in the CR group and 14 patients (56%) in the NR group at the last follow-up. The probability of 5-year OS for the CR and NR group were 56.06% AE 9.2% and 51.85% AE 10.83%, respectively (P ¼ .6408, Figure 3A ), whereas the EFS for the CR and NR groups were 53.42% AE 9.14%, and 51.59% AE 10.61%, respectively (P ¼ .7448, Figure 3B ). Eight patients (24%) experienced relapse after PBSCT in the CR group and seven patients (28%) in the NR group. The probability of 5-year RR for the CR and NR groups were 29.7% AE 9.04% and 33.44% AE 10.86%, respectively (P ¼ .6555, Figure 3C ). Six patients in the CR group and 6 patients in the NR group died of transplant-related complications. The probability of 5-year TRM for the CR and NR groups were 22.13% AE 8.04% and 28.85% AE 10.02%, respectively (P ¼ .5225, Figure 3D) . Detailed information about patients with CR and NR are listed in Table 3 .
DISCUSSION
PBSCs replaced bone marrow as a stem cell source in approximately 100% in the autologous and approximately 75% in the allogeneic transplantation setting [16] . Based on a variety of multicenter trials in leukemia patients, PBSCT, compared with bone marrow transplantation, has a stronger GVL effect, faster engraftment, less transplantation-related complications, and a reduced treatment cost [30] [31] [32] [33] . A large registry reported that the incidence of cGVHD at 1 year was significantly greater in patients after PBSCT, and TRM and leukemia-free survival rates were in favor of patients undergoing PBSCT in advanced stages of leukemia [15] . The role of stem cell transplantation in rAML is well established and has been confirmed as mandatory for cure. It can reduce relapse significantly and induce long-term disease remission [34] [35] [36] . To verify and improve the outcome of patients with rAML undergoing PBSCT, the possible transplant-related factors that should affect outcome were evaluated in the study presented here. It thus appears possible to define patients with refractory or relapsed disease who require more attention and therapy if we are to achieve results comparable with those of non-rAML patients.
For patients with rAML, the most important thing is to reduce the relapse rate and prolong survival. Almost all previous publications have found a lower rate of survival and higher rate of relapse for patients in refractory or relapsed status before HSCT versus those in nonrefractory or relapsed status. In a study with primary refractory AML, the 3-year disease-free survival, OS, and RR were 31%, 30%, and 51%, respectively [13] . With high-dose chemotherapy before HSCT, 5-year EFS was 52% for refractory AML patients [37] . In our study, we found that the 5-year OS was approximately 54% in the rAML group, a promising and acceptable result, although it was still lower than that in the non-rAML group. Apparently, the main reason for the lower OS in the rAML group was that most patients died of relapse and transplant-related disease. It is conceivable that a higher proportion of tumor cells in rAML patients presents a higher relapse rate after HSCT [38] [39] [40] , but, interestingly, no significant difference was found in EFS and RR between rAML and non-rAML in the current cohort.
Considering the peripheral blood as graft, we hypothesized that the stronger GVL effect plays a part in reducing the incidence of relapse and improving the EFS. In addition, early rapid tapering of immunosuppressants and prophylactic DLI for rAML patients may also play an important role. The indubitable existence of a GVL effect is difficult to prove directly, and it is the beneficial aspect of the graft-versushost phenomenon, in particular cGVHD, after allogeneic transplant [41] [42] [43] . Although poorly controlled GVHD is associated with significant morbidity and mortality, there may be also benefits from the GVL effect, including facilitation of the engraftment process or prevention/treatment of leukemia relapse [44] .
We found no statistical significance in terms of the 5-year EFS, RR, and TRM between rAML and non-rAML patients, whereas the incidence of cGVHD in the rAML group was higher than that in the non-rAML group (P ¼ .041).We presumed that the GVL effect triggered by cGVHD might play an important role in prevention of relapse, although GVHD was not a significant predictor of survival in multivariate analysis. CsA was withdrawn rapidly in a stepwise fashion to avoid overwhelming GVHD reactions if aGVHD did not develop at the early stage [20] . In our study, 71% of rAML patients discontinued CsA rapidly, which might enhance the GVL effect and thus result in a higher EFS in rAML patients.
Prophylactic DLI can also augment allogeneic immunemediated antileukemia effect after allo-HSCT, and it has been proven to induce remissions in patients with relapsed hematologic malignancies after transplantation [45, 46] . Prophylactic DLI has also been used as part of transplant protocols in patients who have not relapsed, and it is intended to facilitate establishment of full donor chimerism and potentiation of the antitumor effect [47] . Although we found that 81% of rAML patients had cGVHD after PBSCT, and it was higher than non-rAML patients, the rapid tapering of immunosuppressants for GVHD in the early stage after PBSCT and prophylactic DLI have an acceptable toxicity profile and may be a better approach to treating rAML.
The outcome of HSCT is associated with leukemia load before transplantation, and this is one of the most important factors predicting long-term survival in acute leukemia [48] . What is currently debated is whether a trial of reinduction chemotherapy before transplantation is beneficial for patients with refractory and/or relapsed AML. For rAML patients unlikely to respond, reinduction attempts may be detrimental, leading to added organ toxicity and possible increased tumor resistance. What should we do for these patients? It is reported that the 2-year OS rates were 66%, 40%, and 23% for patients in CR and with active disease without and with circulating blasts at HSCT, respectively [49] . In our study, we found that the patients with NR disease status before PBSCT also had a similar outcome compared with those in CR. The rAML patients transplanted after CR may have less advanced diseases but are likely to have been exposed to more chemotherapies, which may compromise their ability to withstand conditioning. Therefore, in our analysis rAML patients in CR versus NR have nearly identical survival.
For patients with NR disease status, we can also choose allo-PBSCT as a salvage therapy method. Moreover, the rAML patients who achieved CR before transplantation still needed MNC indicates mononuclear cells.
* Poor risk: Philadelphia (Ph) chromosome-positive t(9;22), À5/ del5q, À7, 3q, or 11p abnormalities; translocations t(4;11), t(1;19), t (3;3), t(6;9), inv (3) (q21;q26.2); and complex karyotypes (three or more chromosome abnormalities).
to be exposed to a conditioning regimen. The toxicity of the myeloablative conditioning regimen administered before transplantation remains the main factor leading to high morbidity and mortality [50] , especially for those refractory/ relapsed patients undergoing intensive remission induction chemotherapy. RIC regimens have emerged as an attractive modality to decrease TRM. Multivariate analysis in our report also showed that noneRIC-FBA conditioning regimen was significantly associated with a higher risk of TRM. From this we can see that the RIC-FBA regimen can reduce the incidence of transplant-related disease and improve the long-term prognosis of rAML patients after PBSCT. A report from our center showed that the probability of OS in AML patients in first and second CR with RIC-FBA regimen at þ100 days,1 year. and 2 years was 97.10%, 81.84%, and 75.07%, respectively, whereas the probability of disease-free survival were 97.10%, 80.27%, and 73.62%, respectively [51] . In this report, we also used the RIC-FBA regimen in 18 rAML patients. Although the number of patients is insufficient and the observation time is short, we await the complete analyses of the results.
Donor type is an important factor in allo-HSCT. In China, most families have only one child because of national policies, and it is more difficult to find a matched related donor than in other countries. Therefore, transplantation using an unrelated donor is then considered with preference. Transplantation using a matched unrelated donor offers outcomes comparable with related donor HSCT due to current molecular-based HLA typing and improvements in conditioning regimens and/or supportive care [52, 53] . Similar results have also been found in our study. The OS, EFS, RR, and TRM rates of rAML patients between the related donor group and unrelated donor group were not statistically different (data not shown).
In conclusion, our data suggest that allo-PBSCT is a promising and safe choice for the treatment of rAML, even with a higher leukemia burden. Except for OS, there was no statistically significant difference between rAML and nonrAML patients in terms of EFS, RR, or TRM, partially due to the rapid tapering of immunosuppressants in the early stage and prophylactic DLI after allo-PBSCT. The rAML patients who were not able to achieve CR before transplantation could also benefit from allo-PBSCT. Our small number of patients definitely makes some strong conclusions difficult at this stage, but it would be interesting to see what happens with a longer follow-up of rAML patients.
